Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 57,000 shares, a decrease of 18.6% from the October 31st total of 70,000 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average trading volume of 36,200 shares, the days-to-cover ratio is currently 1.6 days.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH upped their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a report on Monday, October 21st.

Institutional Trading of Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. Wedbush Securities Inc. increased its stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the period. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Trading Up 9.7 %

Shares of NASDAQ MRKR opened at $3.50 on Monday. Marker Therapeutics has a fifty-two week low of $2.44 and a fifty-two week high of $6.16. The business’s 50 day moving average price is $3.35 and its 200-day moving average price is $3.85.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.